Search clinical trials for: Afatinib Dimaleate

Total 2499 results

Pfizer

Completed

Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

Carcinoma, Renal Cell

United States, Spain, Japan, Germany, Czechia, Russian Federation
Chinese University of Hong Kong

Completed

Nasopharyngeal Carcinoma (NPC) Axitinib

Recurrent or Metastatic NPC

Hong Kong
PETHEMA Foundation

Recruiting

Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

Acute Lymphoblastic Leukemia Ph Positive

Spain
Sidney Kimmel Comprehensive Cancer Center at Johns...
Massachusetts General Hospital; Washington University School of Medicine; Gla... and other collaborators

Completed

Concentration and Activity of Lapatinib in Vestibular Schwannomas

Neurofibromatosis 2 | Vestibular Schwannoma | Acoustic Neuroma | NF2 | Auditory Tumor

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb

Completed

BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate

Leukemia

United States
Yonsei University

Completed

A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)

Fibromatosis

Korea, Republic of
University of Wisconsin, Madison
Pfizer

Completed

Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib

Solid Malignancies | Metastatic Castrate-resistant Prostate Cancer

United States
Swiss Group for Clinical Cancer Research

Completed

Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumor

France, Switzerland, Germany, Finland
St. Justine's Hospital

Terminated

Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas

Plexiform Neurofibromas

Canada
Spanish Cooperative Group for the Treatment of...

Terminated

Axitinib as Maintenance Treatment in Patients With Metastatic CRC (TTD-11-01)

Colorectal Carcinoma

Spain
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib

Lung Cancer

United States
Cttq
Ruijin Hospital

Unknown

Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

Chronic Myeloid Leukemia
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

Leukemia

United States
Novartis

Completed

Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)

Chronic Myelogenous Leukemia in Chronic Phase
Novartis

Completed

Effects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass Pollen

Seasonal Allergic Rhinitis

United Kingdom
Nanfang Hospital, Southern Medical University

Not yet recruiting

PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer Extensive Stage
China Medical University, China

Recruiting

PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma

Gastric Cancer | AFP

China
Qilu Pharmaceutical Co., Ltd.

Unknown

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

Non-small-cell Lung Cancer

China
Peking University Cancer Hospital & Institute

Unknown

Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma

Melanoma
Massachusetts General Hospital
National Comprehensive Cancer Network

Unknown

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

Non Small Cell Lung Cancer

United States
Boehringer Ingelheim

Completed

GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

Carcinoma, Non-Small-Cell Lung

Germany
Boehringer Ingelheim

Approved for marketing

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Boehringer Ingelheim

Terminated

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

Carcinoma, Non-Small-Cell Lung | ErbB Receptors

United States
Groupe Hospitalier Paris Saint Joseph

Withdrawn

Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex (THEN)

SMALL CELL LUNG CARCINOMA

France
Fujian Cancer Hospital

Recruiting

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Immunotherapy | Gastrict Cancer

China
Nanfang Hospital of Southern Medical University

Recruiting

A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer

Gastric Cancer

China
Sun Yat-sen University
Guangdong Provincial Hospital of Traditional Chinese Medicine; Guangdong Provincial...

Active, not recruiting

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

Colorectal Cancer | Microsatellite Instability High

China
Shenzhen People's Hospital

Unknown

Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC (AFLC)

NSCLC | Apatinib | EGFR-TKI

China
Li Huiping

Not yet recruiting

A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer

Advanced Breast Cancer
University of Pittsburgh

Completed

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

Head and Neck Cancer | Non Small Cell Lung Cancer

United States
University College, London
Boehringer Ingelheim

Completed

Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity (DARWIN1)

Non-small Cell Lung Cancer

United Kingdom
University Health Network, Toronto
Boehringer Ingelheim

Completed

A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene

Solid Tumors

Canada
National Cancer Centre, Singapore

Terminated

Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC

Non-small Cell Lung Cancer | Leptomeningeal Disease | Central Nervous System Metastases

Singapore
Santosh Kesari
Boehringer Ingelheim

Completed

Safety Study of Afatinib for Brain Cancer

Brain Cancer

United States
University of Alabama at Birmingham

Terminated

Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma

Penile Squamous Cell Carcinoma (PSCC)

United States
Akeso

Recruiting

A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma | First-line Treatment

China
Asan Medical Center

Active, not recruiting

Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI

Gastrointestinal Stromal Tumors

Korea, Republic of
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib (CML0609)

Chronic Myeloid Leukaemia

Italy
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone

Breast Cancer | Metastatic Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

Malignant Mesothelioma

United States
Centre Oscar Lambret
Novartis; National Cancer Institute, France

Terminated

Imatinib in Adult Patients With Metastatic Ocular Melanoma (O-Mel-Inib)

Melanoma

France
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Italy
GlaxoSmithKline

Completed

Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma (VEG102857)

Glioma
Azienda Ospedaliera Universitaria Policlinico
Università Politecnica delle Marche

Unknown

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

Systemic Sclerosis

Italy
Central European Leukemia Study Group

Unknown

Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

Chronic Myeloid Leukemia

Austria
Zhongshan Hospital Xiamen University

Recruiting

Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer

Ovarian Cancer

China
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma (IMplus)

Head and Neck Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer (APPROVE)

Platinum-resistant Recurrent Ovarian Cancer

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer

Small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer

Ovarian Cancer

Search clinical trials for: Afatinib Dimaleate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations